2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee Antoine VergerHenryk BarthelEric Guedj Editorial 16 July 2022 Pages: 3599 - 3606
Spatial density and tumor dosimetry are important in radiation segmentectomy with 90Y glass microspheres Carlo ChiesaStefania MazzagliaMarco Maccauro Editorial 11 May 2022 Pages: 3607 - 3609
Unnatural amino acids offer new hope for accurate bacterial infection PET imaging in prosthetic joint infection Peter J. H. Scott Editorial 02 June 2022 Pages: 3610 - 3612
Present and future of target therapies and theranostics: refining traditions and exploring new frontiers—highlights from annals of Nuclear Medicine 2021 Cristiano PiniFabrizia GelardiMartina Sollini Editorial 23 July 2022 Pages: 3613 - 3621
Letter to the editor regarding “Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival” Maria José Veloza VegaManuela GalloPatricia Bernal Letter to the Editor 15 June 2022 Pages: 3622 - 3623
Total-body pediatric PET is ready for prime time Mehdi DjekidelRahaf AlSadiOthmane Bouhali Letter to the Editor 20 June 2022 Pages: 3624 - 3626
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T Eline A. M. RuigrokGiulia TamborinoJulie Nonnekens Original Article Open access 12 May 2022 Pages: 3627 - 3638
Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer Viviane J. TschanFrancesca BorgnaCristina Müller Original Article Open access 30 May 2022 Pages: 3639 - 3650
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy Dirk ZboralskiAileen HoehneFrank Osterkamp Original Article Open access 24 May 2022 Pages: 3651 - 3667
Imaging PARP with [18F]rucaparib in pancreatic cancer models Chung Ying ChanZijun ChenBart Cornelissen Original Article Open access 26 May 2022 Pages: 3668 - 3678
Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET) Samantha RossanoTakuya ToyonagaRichard E. Carson Original Article 28 May 2022 Pages: 3679 - 3691
Fibrin-targeting molecular MRI in inflammatory CNS disorders Johannes LohmeierRafaela V. SilvaMarcus R. Makowski Original Article Open access 04 May 2022 Pages: 3692 - 3704
[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity Zachary T. RosenkransChristopher F. MasseyReinier Hernandez Original Article 12 May 2022 Pages: 3705 - 3716
Applications of Generative Adversarial Networks (GANs) in Positron Emission Tomography (PET) imaging: A review Ioannis D. ApostolopoulosNikolaos D. PapathanasiouGeorge S. Panayiotakis Review Article 22 April 2022 Pages: 3717 - 3739
Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans Abolfazl MehranianScott D. WollenweberDaniel R. McGowan Original Article Open access 04 May 2022 Pages: 3740 - 3749
Artificial intelligence-based PET denoising could allow a two-fold reduction in [18F]FDG PET acquisition time in digital PET/CT Kathleen WeytsCharline LasnonCyril Jaudet Original Article Open access 20 May 2022 Pages: 3750 - 3760
Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans Ilona PolvoyYoungho SeoMichael A. Ohliger Original Article Open access 23 June 2022 Pages: 3761 - 3771
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth Mariska ReinartzEmma Susanne LuckettRik Vandenberghe Original Article Open access 06 May 2022 Pages: 3772 - 3786
Development and validation of a radiomic model for the diagnosis of dopaminergic denervation on [18F]FDOPA PET/CT Victor ComteHugo SchmutzOlivier Humbert Original Article Open access 14 May 2022 Pages: 3787 - 3796
Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation Justin P. WrightJason R. GoodmanKelly A. Conway Original Article Open access 21 May 2022 Pages: 3797 - 3808
Spatial normalization and quantification approaches of PET imaging for neurological disorders Teng ZhangShuang WuMei Tian Review Article 28 May 2022 Pages: 3809 - 3829
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients Anna SundlövKatarina Sjögreen GleisnerJohanna Svensson Original Article Open access 22 April 2022 Pages: 3830 - 3840
In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy Aleksandra SygułaAleksandra LedwonDaria Handkiewicz-Junak Original Article 03 May 2022 Pages: 3841 - 3851
Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 Arnoldo PiccardoNathalie L. AlbertPietro Zucchetta Guidelines Open access 10 May 2022 Pages: 3852 - 3869
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis Egon BurianBenjamin PallaFelix G. Gassert Original Article Open access 24 May 2022 Pages: 3870 - 3877
Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer Olivier HumbertMatteo BaucknehtJosiane Otto Original Article Open access 14 May 2022 Pages: 3878 - 3891
Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors S. Ali MontazeriCynthia De la Garza-RamosBeau B. Toskich Short Communication 20 April 2022 Pages: 3892 - 3897
Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer Halil KömekCanan CanEbubekir Gündeş Original Article 17 May 2022 Pages: 3898 - 3909
Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies Bernd VollnbergIan AlbertsAli Afshar-Oromieh Short Communication Open access 28 April 2022 Pages: 3910 - 3916
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI Riccardo LaudicellaJan H. RüschoffIrene A. Burger Original Article Open access 18 April 2022 Pages: 3917 - 3928
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference Rick HermsenEsmée B. C. WedickJean-Paul A. van Basten Original Article 11 May 2022 Pages: 3929 - 3937
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens Wojciech CytawaStefan KircherAndreas K. Buck Original Article 12 May 2022 Pages: 3938 - 3949
[18F]PSMA-1007 PET/CT in the detection of neoplastic lumbosacral plexopathy as an emerging and underestimated spread of prostate cancer A.-L. DeleuN. Ahmadi BidakhvidiK. Goffin Image of the Month 04 May 2022 Pages: 3950 - 3951
Prostate cancer cardiac metastasis detected on serial imaging with [68Ga] PSMA-11 PET/CT Jeeban Paul DasRandy Yeh Image of the Month 11 May 2022 Pages: 3952 - 3953
Neglected giant benign phyllode tumor of the breast Marc-Antoine BenderraClement FerrierKhaldoun Kerrou Image of the Month 18 May 2022 Pages: 3954 - 3955
Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T Eline A. M. RuigrokGiulia TamborinoJulie Nonnekens Correction Open access 26 May 2022 Pages: 3956 - 3957